

1 **Lifestyle Profiling Using Wearables and**

2 **Prediction of Glucose Metabolism in Individuals with Normoglycemia or Prediabetes**

3  
4  
5 **Lifestyle Profiling for Glucose Prediction Using Wearables**

6  
7  
8 Heyjun Park<sup>1,2\*</sup>, Ahmed A. Metwally<sup>1,\*</sup>, Alireza Delfarah<sup>1</sup>, Yue Wu<sup>1</sup>, Dalia Perelman<sup>1</sup>, Majid  
9 Rodgar<sup>1</sup>, Caleb Mayer<sup>1</sup>, Alessandra Celli<sup>1</sup>, Tracey McLaughlin<sup>3</sup>, Emmanuel Mignot<sup>4</sup>, Michael  
10 Snyder<sup>1,5</sup>

11  
12  
13 <sup>1</sup>Department of Genetics, Stanford University, Stanford, CA 94305, U.S.A. <sup>2</sup>Department of  
14 International Health, Johns Hopkins Bloomberg School of Public Health, MD 21205, U.S.A.

15 <sup>3</sup>Department of Medicine, Stanford University, Stanford, CA 94305, U.S.A. <sup>4</sup>Center for Sleep  
16 Sciences and Medicine, Stanford University School of Medicine, Palo Alto, CA 94304, U.S.A.

17 \* These authors contributed equally

18 <sup>5</sup>Corresponding author: Michael Snyder, [mpsnyder@stanford.edu](mailto:mpsnyder@stanford.edu)

19 Keywords: Lifestyle, Metabolic Phenotyping, Continuous Glucose Monitoring, Insulin Resistance,  
20 Type 2 Diabetes

27 **Abstract**

28 This study examined the relationship between lifestyles (diet, sleep, and physical activity) and  
29 glucose responses at a personal level. 36 healthy adults in the Bay Area were monitored for  
30 their lifestyles and glucose levels using wearables and continuous glucose monitoring  
31 (NCT03919877). Gold-standard metabolic tests were conducted to phenotype metabolic  
32 characteristics. Through the lifestyle data (2,307 meals, 1,809 nights, and 2,447 days) and  
33 231,206 CGM readings from metabolically-phenotyped individuals with normoglycemia or  
34 prediabetes, we found: 1) eating timing was associated with hyperglycemia, muscle insulin  
35 resistance (IR), and incretin dysfunction, whereas nutrient intakes were not; 2) timing of  
36 increased activity in muscle IS and IR participants was associated with differential benefits of  
37 glucose control; 3) Integrated ML models using lifestyle factors predicted distinct metabolic  
38 characteristics (muscle, adipose IR or incretin dysfunction). Our data indicate the differential  
39 impact of lifestyles on glucose regulation among individuals with different metabolic phenotypes,  
40 highlighting the value of personalized lifestyle modifications.

41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

## 53 Introduction

54 Type 2 diabetes continues to rise, affecting 34.1 million people in the U.S. and 537  
55 million adults worldwide<sup>1</sup>. Moreover, 88 million U.S. adults are estimated to have prediabetes,  
56 and up to 70% of these are expected to develop type 2 diabetes within four years<sup>2</sup>. Therefore, it  
57 is critical to prevent this at-risk population from converting to type 2 diabetes and reduce a  
58 significant public health burden. Many studies have shown that lifestyle modification is a  
59 powerful and cost-effective means to prevent and manage type 2 diabetes<sup>3</sup>.

60 Diet, sleep, and physical activity are core lifestyle behaviors that are highly individualized  
61 and can be modified. Although many studies have investigated the effect of lifestyle factors on  
62 glucose control, it is still not fully understood, partly due to the challenge of capturing habitual  
63 lifestyle patterns among free-living individuals, especially as they relate to blood glucose control.  
64 For example, while written food questionnaires and 24-hour dietary recalls are widely used  
65 methods to collect food and beverage consumption data of study participants, these methods  
66 record eating events for short durations retrospectively, which may lead to inaccuracy. Similarly,  
67 many studies assess participants' sleep, but usually in a laboratory and only for a few days.  
68 Consequently, it has been challenging to accurately measure the lifestyle habits of free-living  
69 individuals in their natural environments with enough granularity to understand relationships  
70 among the various lifestyle parameters.

71 Modern technologies such as wearable sensors and smartphone applications have  
72 enabled 24-hour monitoring and the capture of lifestyle behaviors in real-time for many  
73 continuous days<sup>4,5</sup>. A growing body of epidemiological and physiological evidence points to  
74 close interactions of lifestyle behaviors with the circadian clock system. The circadian clock is a  
75 timekeeping system that optimizes organ functions by regulating thousands of genomic  
76 activities and metabolic processes at different times of the day<sup>6-8</sup>. Light, food, and exercise can  
77 serve as external signals to synchronize the clock<sup>9</sup>, which by itself regulates glucose control and

78 sleep. Moreover, sleep deprivation/curtailment has also been shown to adversely impact  
79 glucose levels<sup>10,11</sup>. Therefore, circadian desynchronization induced by inappropriate timing of  
80 lifestyle behaviors has been suggested to disrupt physiological responses and may have  
81 adverse effects, including type 2 diabetes<sup>12,13</sup>. To date, most studies have explored the effect of  
82 only one or two lifestyle behaviors on glucose control. The simultaneous interrelationship of all  
83 three behaviors has not been explored.

84 By leveraging the power of digital health monitoring technologies, we expect lifestyle  
85 factors (i.e., diet, sleep, and physical activity) would have closely intertwined and concurrent  
86 dynamic interactions. We also expect that these factors would be associated not only with  
87 glucose control in individuals with prediabetes using standard clinical labs and CGM measures  
88 but also would further reveal novel relationships with metabolic characteristics such as insulin  
89 resistance or incretin dysfunction. Therefore, the goals of this study were 1) to deeply profile  
90 temporal patterns of the lifestyles; 2) to examine the inter-relations of diet, sleep, and physical  
91 activity features; 3) to quantify associations of lifestyle habits with glucose control using  
92 continuous glucose monitoring; and 4) to predict glucose metabolic characteristics (i.e., insulin  
93 resistance, beta-cell dysfunction, incretin dysfunction, all of which are known to lead to type 2  
94 diabetes) based on lifestyle habits. For metabolic characteristics, we conducted standardized  
95 glucose metabolic tests such as OGTT, an insulin suppression test, and an isoglycemic  
96 intravenous glucose infusion test.

97

## 98 **Results**

### 99 **Cohort characteristics and data collection**

100 By leveraging the power of real-time digital health monitoring technologies, we collected  
101 the habitual lifestyle data of 2,307 meals (a median 20.5 days of food logs per participant),  
102 1,809 days of sleep (a median 47.5 nights per participant), 2,447 days of physical activity (a  
103 median of 64 days per participant), and 231,206 CGM readings (a median 36.5 days per

104 participant) from 36 healthy adults (> 18 y of age; median 57.6y; 17 males and 19 females;  
105 **Figure 1**). Baseline characteristics and clinical lab results of study participants are described in  
106 **Table 1**. The participants were grouped into those with prediabetes/type 2 diabetes (n=20; 19  
107 prediabetes and one with type 2 diabetes) or normoglycemia (n=16) following American  
108 Diabetes Association HbA1c criteria (normoglycemic (HbA1c<5.7%; HbA1c< 39 mmol/mol),  
109 prediabetes (5.7% <HbA1c<6.5%; 39 mmol/mol <HbA1c<48 mmol/mol), and type 2 diabetes  
110 (HbA1c>6.5%; HbA1c>48 mmol/mol). Demographic characteristics, including age, sex, BMI,  
111 ethnicity, statin use, smoking, season at study entry, self-reported exercise in minutes, and  
112 systolic/diastolic blood pressure, were not statistically different between prediabetes/type 2  
113 diabetes and normoglycemia. However, people with prediabetes/type 2 diabetes showed higher  
114 fasting plasma glucose (P=1.61e-3), fasting insulin (P=9.30e-3), and triglyceride (P=0.0142)  
115 despite no differences in other laboratory tests.

116

### 117 **Individualized differences in glucose dysregulation by metabolic tests**

118 Participants underwent gold standard metabolic tests after 10-h overnight fasting,  
119 including an oral glucose test (OGTT), insulin suppression test (IST), and isoglycemic  
120 intravenous glucose infusion test (IIGI). The metabolic test results determined participants'  
121 metabolic characteristics, such as insulin resistance, beta-cell dysfunction, and incretin  
122 dysfunction. Details are presented in the **Methods** section.

123 People with prediabetes/type 2 diabetes participants showed significantly higher glucose  
124 levels at 2 hours of OGTT, higher 24h mean sensor-glucose, higher 24h max sensor-glucose  
125 value, more time spent in hyperglycemic range (>140 mg/dL), and higher sensor-glucose  
126 variation than the normoglycemic group (P <0.05; **Supplementary Figure 1**). Additionally,  
127 participants were categorized: (1) muscle IS when SSPG <120 mg/dL (68.2±20.9 mg/dL) and  
128 muscle IR when SSPG >120 mg/dL (190±52.0 mg/dL). Our determination of IR aligns with the  
129 50% of the SSPG distribution among 490 healthy volunteers that include moderate elevations of

130 SSPG<sup>14</sup>; (2) normal beta-cell function when the disposition index (DI) >2.2 (2.91±0.313),  
131 intermediate when  $1.2 \leq DI \leq 2.2$  (1.73±0.32), and dysfunction when  $DI < 1.2$  (0.794±0.206); (3)  
132 Incretin normal function when incretin effects (IE) >64% (72.6±6.12), intermediate when  $39\% \leq$   
133  $IE \leq 64\%$  (52.6±8.31), and dysfunction when  $IE < 39\%$  (25.2±11.2); (4) adipose IS when adipose  
134 IR (FFA) <0.15 (0.144±0.0547), intermediate when  $0.15 < \text{adipose IR} < 0.5$  (0.418±0.132), and IR  
135 when adipose IR > 0.5 (0.769±0.0768); and (5) hepatic IS when HIR-index >3.95 (3.75±0.242),  
136 intermediate when  $3.95 \leq \text{HIR-index} \leq 4.8$  (4.36±0.250) and IR when HIR-index >4.8  
137 (4.91±0.0659).

138

139 **Habitual meal timing patterns are associated with hyperglycemia, insulin resistance, and**  
140 **incretin response.**

141 To our knowledge, the relationship between meal timing and different metabolic  
142 characteristics has not been explored previously. Briefly, the meal timing profiles for each of the  
143 36 participants were determined by segmenting the food and beverage consumption (hereafter  
144 referred to as “meal”) periods into six windows: 1) 05:00 and 08:00; 2) 08:00 and 11:00; 3)  
145 11:00 and 14:00; 4) 14:00 and 17:00; 5) 17:00 and 21:00; and 6) 21:00 and the next day 05:00.  
146 These intervals reflect the major periods of food consumption. Subsequently, the energy intake  
147 contribution from each meal timing period relative to the total daily energy intake was  
148 determined.

149 Participants had highly variable inter-individual meal timing patterns enabling an  
150 investigation between meal timing and glucose dysregulation (**Figure 2A**). We used a principal  
151 component analysis (PCA) based on six meal timing features to identify hidden dietary patterns  
152 of the food consumption timing and their relationship to glucose dysregulation pathophysiologies.  
153 Notably, the cohort clearly separated into two clusters by their HbA1c levels based on the meal  
154 timing features (**Figure 2B**). Specifically, individuals with lower  
155 HbA1c levels are positioned at the top left of the PCA plot, whereas those with higher

156 HbA1c levels are located at the bottom right indicating distinct behavior patterns in their timing  
157 of food consumption. A multiple linear regression (MLR) analysis identified daily time intervals  
158 where the separation arises, further substantiating this conclusion. Relative to participants with  
159 lower HbA1c, participants with higher HbA1c had lower energy consumption from the meal  
160 consumed between 14:00-17:00 (adjusted- $P=0.021$ ), as well as higher energy consumption  
161 from the meals 17:00-21:00 (adjusted- $P=0.079$ ) and 5:00-8:00 (adjusted- $P=0.059$ ) (**Figure 1C**).  
162 Similarly, the cohort was separated into three clusters by incretin function (IE%) based on the  
163 meal timing features (**Figure 2D**). The regression models confirmed that participants with  
164 reduced incretin function had lower energy intakes from the meal 14:00-17:00 (adjusted-  
165  $P=0.027$ ) and higher energy intakes from the meals 17:00-21:00 (adjusted- $P=0.018$ ) and 11:00-  
166 14:00 (adjusted- $P=0.028$ ) (**Figure 2E**). A similar analysis was performed for muscle insulin  
167 sensitivity (IS vs. IR) for both PCA (**Figure 2F**) and regression analyses (**Figure 2G**; adjusted-  
168  $P=0.049$  for the window 17:00-21:00). However, the cohort was not separated into clusters by  
169 beta-cell function (disposition index), indicating no association.

170 The distribution of timing-related diet data are shown in **Figure 3A**. Violin plots were  
171 used to represent both summary statistics and density information of the data. Sleep-related diet  
172 parameters were derived through time-matching, meaning that the diet and sleep data were  
173 collected concurrently. Furthermore, we comprehensively assessed associations of 36 diet  
174 parameters (i.e., nutrients, food groups, eating timing; **Supplementary Table 1**) with CGM  
175 profiles and glucose metabolic outcomes (**Figure 3**). Briefly, relevant diet features were  
176 selected through the LASSO selection (**Supplementary Table 2**), followed by building MLR  
177 models incorporating the selected diet features and potential confounding variables such as age,  
178 sex, ethnicity, and BMI. This combined approach reduces the data dimensionality and improves  
179 overall model performance. In the forest plot (**Figure 3B**), each horizontal panel corresponds to  
180 a specific glucose outcome where the point estimate (beta coefficient) of each diet parameter is  
181 present along with confidence intervals. This visualization provides a concise summary of

182 multiple regression models within one graph. The plot highlights associations that achieved  
183 statistical significance (BH-adjusted  $P < 0.1$ ) between diet parameters and glucose outcomes.  
184 Specifically, the energy proportion of the meal 14:00-17:00 to the total daily energy intake was  
185 inversely associated with fasting plasma glucose. Conversely, higher energy consumption from  
186 the meal 17:00-21:00 was associated with less time spent in the target glucose range (70-100  
187 mg/dL) during nighttime and more time spent in the hyperglycemic ( $>100$  mg/dL) range. In  
188 addition, while higher carbohydrate intakes from non-starchy vegetables were related to lower  
189 next-day mean glucose levels, more carbohydrate intakes from starchy vegetables were  
190 associated with higher fasting plasma glucose, higher HbA1c, and higher 24-hour mean glucose.  
191 Finally, higher carbohydrate intakes from snacks were also associated with more time spent in  
192 the hyperglycemic range ( $>140$  mg/dL) for 24 hours, higher nighttime mean glucose, and more  
193 time spent in the hyperglycemic range for the next day.

194

#### 195 **Variation in sleep timing is associated with hyperglycemia and incretin function.**

196 To investigate the relationship of sleep parameters with glucose control and metabolic  
197 characteristics, real-time sleep monitoring data was estimated from participants using a Fitbit  
198 Ionic band (Fitbit, Inc., San Francisco, CA). We extracted and derived 14 sleep features and  
199 observed considerable between-person variability for each sleep parameter (**Figure 4A**). Using  
200 feature selection via LASSO and 10-fold cross-validation (**Supplementary Table 3**), as well as  
201 the MLR (**Figure 4B**), we found that day-to-day variability of sleep features, WASO (wake up  
202 duration after sleep onset), and wake-up time were significantly associated with glucose  
203 outcomes. Specifically, higher variability in sleep efficiency was associated with higher night-  
204 time mean glucose values, more time spent in the night-time hyperglycemic range ( $>100$  mg/dL),  
205 and higher next-day mean glucose values. Moreover, higher variability in bedtime was  
206 associated with higher next-day max glucose values. WASO was related to higher glucose  
207 levels at OGTT 2 hours, and earlier wake-up time was associated with lower incretin effects.



208 These results indicate that a number of sleep parameters are associated with glucose  
209 dysregulation.

210

### 211 **Physical activity habits profiling and the time-dependent association with glucose values**

212 We obtained real-time step count and heart rate data from the Fitbit Ionic band. Using  
213 feature selection via LASSO and 10-fold cross-validation (**Supplementary Table 4**), as well as  
214 the MLR, we observed that having more steps near bedtime was associated with poor nighttime  
215 CGM outcomes in the overall cohort (**Figure 4C**). Specifically, more steps during 1-2 hours  
216 before bedtime were associated with higher nighttime mean glucose values and less time spent  
217 in the nighttime target glucose range. Additionally, more steps taken 1 hour before bedtime  
218 were associated with higher mean glucose values up to the next day. Furthermore, a longer  
219 sedentary duration of the day was associated with shorter time spent in the target glucose range  
220 during the night. Interestingly, a higher step density after having last food was associated with  
221 lower nighttime mean glucose and more time in the nighttime target glucose range.

222 Next, we quantified the association of physical activity with glucose levels as a function  
223 of time. We split the time-series step count and CGM data into 7 circadian-time windows: 1)  
224 05:00 - 8:00; 2) 8:00 - 11:00; 3) 11:00 - 14:00; 4) 14:00 - 17:00; 5) 17:00 - 21:00; 6) 21:00 –  
225 24:00; and 7) 24:00 - the next day 05:00 (**Supplementary Table 5**). To visualize the interaction  
226 effect of step counts and insulin resistance status (i.e., IS and IR) on CGM values at different  
227 times of the day, we plotted the results from linear models fit at each combination of time  
228 windows (**Figure 5A**). Interestingly, insulin resistance status significantly interacted with step  
229 counts to affect glucose values primarily in the time windows at 00:00-05:00, 8:00-11:00, 11:00-  
230 14:00, and 14:00-17:00 denoted by an asterisk (**Figure 5A**). Therefore, a shifted Pearson  
231 correlation analysis with permutation was subsequently performed between step counts and  
232 mean glucose values to examine their temporal relationship by insulin resistance subgroups. A  
233 heatmap with the shading corresponding to the correlation coefficient at the designated

234 combination of time windows was plotted (**Figures 5B-D**). Notably, we found that, in the muscle  
235 IS, steps during 14:00-17:00 were negatively correlated with CGM values within the next 48-  
236 hour time window (**Figure 5B**). Conversely, in the muscle IR, steps during 8:00-11:00 were  
237 associated with lower glucose values within the next day, indicating the significance of activity  
238 timing for glucose levels (**Figure 5C**). In addition, more step counts between 00:00-05:00 were  
239 correlated with higher CGM values for up to the next 48 hours in both the IS and IR groups, with  
240 IR showing stronger correlations.

241

### 242 **Permuted correlation network analysis between diet, sleep, and physical activity habits**

243 Our diet-sleep-activity correlation network with permutation highlighted many significant  
244 correlations among diet, sleep, and activity features, and the diet factors (nutrients, food groups,  
245 eating timing) were central in the complex relationships (Figure 6A). The network plot provides  
246 an intuitive visual representation of relationships among three lifestyle behaviors at a glance. In  
247 this analysis, all three lifestyle factors were time-matched. For food groups, higher rice  
248 consumption was correlated with lower sleep efficiency and longer latency duration. In contrast,  
249 higher legume consumption was correlated with shorter latency and longer total sleep duration.  
250 Higher fruit consumption was also correlated with longer sleep duration. For nutrients, higher  
251 fiber and potassium intakes were correlated to longer sleep duration. While higher saturated fat  
252 intake was correlated to longer sedentary duration, higher vitamin D intake was correlated to  
253 longer active duration. Interestingly, higher energy contribution from the meal between 8:00-  
254 11:00am and longer fasting window were correlated with longer sleep duration, whereas late  
255 eating of the first meal of the day was correlated to lower sleep efficiency. Finally, a longer  
256 duration from waking up to first food eating was correlated to a longer latency.

257

### 258 **Integrated lifestyle machine learning prediction models for glucose metabolic**

### 259 **characteristics**

260 We built comprehensive, integrated machine learning models to predict different  
261 metabolic characteristics based on the whole feature set comprising all lifestyle and  
262 demographic features (**Figure 6B**). First, 12 features emerged for predicting prediabetes/type 2  
263 diabetes and normoglycemic individuals. Among those features, a high proportion of  
264 carbohydrate intake from starchy vegetables relative to the total daily carbohydrate intake  
265 associated with prediabetes, while that from fruits was associated with normoglycemia. Other  
266 features that predicted prediabetes included higher energy intake during 5-9 pm, eating the first  
267 meal late after wake-up, and higher trans fat and sodium intakes.

268 To distinguish muscle insulin resistance classes, longer exercise duration was the only predictor  
269 for muscle insulin sensitivity. Incretin function classes were predicted by four features: higher  
270 BMI, higher fat intake, and higher caloric intake between 5-9 pm predicted incretin dysfunction.

271 To predict adipose insulin resistance classes, 12 features were selected, where high intake of  
272 carbohydrates and fat, high BMI, older age, and longer fasting window predicted adipose insulin  
273 resistance.

274

## 275 **Discussion**

276 The interaction between lifestyle behaviors (i.e., diet, sleep, and physical activity) and  
277 their relationship with glucose regulation are not fully understood. To capture temporal patterns  
278 of habitual lifestyle behaviors and glucose levels in normal participant settings, we leveraged the  
279 power of digital health monitoring technologies such as wearable biosensors, continuous  
280 glucose monitoring (CGM), and smartphone apps. Furthermore, we used deep metabolic  
281 phenotyping using standardized metabolic tests, including OGTT, insulin suppression test, and  
282 isoglycemic intravenous glucose infusion test. Consequently, we obtained the habitual lifestyle  
283 data of 2,307 meals, 1,809 days of sleep, and 2,447 days of physical activity in real-time.

284 Numerous lifestyle features were derived by matching the occurring times recorded and their  
285 concurrent dynamic relationships were explored. CGM data were also synchronized with the

286 lifestyle features based on timestamps. As such, we discovered several novel relationships of  
287 lifestyle habits with glucose outcomes using machine learning algorithms, including glucose-  
288 related measurements (HbA1c, fasting plasma glucose, CGM measures) and metabolic  
289 characteristics (insulin resistance, beta-cell function, incretin function): 1) habitual eating timing  
290 was associated with hyperglycemia, insulin resistance, and incretin dysfunction, whereas  
291 nutrient intake levels were not with these parameters; 2) timing of increased physical activity in  
292 muscle IS and IR participants was associated with the differential benefits of glucose control  
293 with IS displaying activity benefits in the afternoon and IR in the morning; 3) Integrated ML  
294 prediction models demonstrated that a different set of lifestyles predicted distinct metabolic  
295 characteristics such as muscle IR, adipose IR or incretin dysfunction.

296 The relationship between meal timing and different metabolic characteristics has not  
297 been explored previously. From our PCA analyses, the participants with lower HbA1c, higher  
298 incretin effect, and muscle insulin sensitivity clustered together, and the driving features were  
299 increased caloric consumption between 14:00 and 17:00 relative to their total daily caloric intake.  
300 In contrast, the participants with higher HbA1c, lower incretin effect, and insulin resistance  
301 clustered together, and they consumed more calories between 17:00-21:00. This finding is  
302 notable because nutrient intake and food group features failed to show these associations  
303 **(Supplementary Figures 2,3,4,5)**

304 Furthermore, in our comprehensive analysis of all diet parameters and glucose  
305 outcomes, higher energy consumption between 17:00-21:00 was associated with less time  
306 spent in the night-time target glucose range and more time spent in the hyperglycemic range.  
307 This deleterious relationship is not due to total caloric intake, which was similar between the two  
308 groups, indicating that food timing affects glucose levels, possibly through its effects on, or due  
309 to, circadian physiology. These results support previous work showing associations of night-time  
310 meals with higher blood glucose, insulin, and HbA1c levels in both healthy and individuals with  
311 diabetes<sup>15,16</sup>. One possible explanation may be a partial desynchrony of food-entrainable

312 peripheral clocks with the central clock in the presence of high-caloric dinners in some animal  
313 studies<sup>17,18</sup>. In addition, the significant association of higher caloric intake 14:00-17:00 with lower  
314 fasting plasma glucose suggests the beneficial effects of afternoon snacks or early dinner on  
315 glucose control. Although one might speculate that the benefits of eating more during this  
316 window may be through suppression of higher meal consumption later, our further analyses  
317 showed that the higher caloric intake 14:00-17:00 was still significantly related to fasting glucose  
318 regardless of caloric intakes of later meals (meals 17:00- 21:00 and 21:00-5:00 next day). In line  
319 with these results, snack consumption before dinner was suggested to enhance beta cell  
320 responsiveness<sup>19</sup>. Overall, the findings from eating habits highlight the importance of monitoring  
321 eating habits--not only meal composition but also timing--for preventing type 2 diabetes.

322 Our data showed that irregular sleep timing and efficiency were associated with higher  
323 insulin resistance and higher glucose values from CGM data, underscoring the importance of  
324 regular sleep hygiene. Irregular sleep habits and nighttime disruption, perhaps due to untimely  
325 light exposure, may result in an abnormal phase relationship with peripheral metabolic clocks for  
326 glucose control homeostasis. Although it has been documented that shift workers with irregular  
327 sleep-wake schedules showed elevated insulin resistance<sup>20,21</sup>, our data support that free-living  
328 individuals who are not shift workers but have high day-to-day variations in their sleep schedule  
329 also have poor glucose regulation (**Supplementary Figure 6**). Additionally, our findings  
330 demonstrate associations between variance in sleep disruption (WASO) throughout the night  
331 and higher glucose levels during the OGTT test. These results highlight the significance of  
332 minimizing variations in sleep fragmentation across nights beyond the known negative impact of  
333 sleep fragmentation on glucose control as previously reported<sup>22-24</sup>. In addition, sleep timing (i.e.,  
334 later wake-up time) was also associated with better incretin effects irrespective of total sleep  
335 duration. Because the median wake-up time of our cohort is 6:56 am, waking up later than ~7  
336 am might be beneficial for incretin function. Incretins respond to meal ingestion, and they have  
337 diurnal rhythms in secretion<sup>25</sup>, with slower release at night compared to daytime. Furthermore,

338 one RCT study<sup>26</sup> showed the major effects of nocturnal light exposure on baseline and  
339 postprandial GLP-1 levels independent of sleep deprivation. Therefore, light exposure induced  
340 by habitual early wake-up time may decrease incretin function, compromising the incretin-  
341 stimulated insulin secretion in the pancreas. Future studies investigating the underlying  
342 mechanism mediating these effects are warranted.

343 Notably, in our study, the timing of increased physical activity was associated with  
344 differential benefits of glucose control across different metabolic conditions. We found significant  
345 time series interactions between step counts and insulin resistance status to influence sensor-  
346 glucose levels, suggesting potential differences in the response of CGM values to activity  
347 between the IS and IR groups (**Figure 5A, Supplementary Figure 7**). Indeed, our subgroup  
348 analyses revealed that the muscle IR group showed subsequent lower CGM mean values when  
349 increasing steps during the morning (8:00–11:00 am). In contrast, the muscle IS group had  
350 subsequent lower CGM mean values when increasing steps during the afternoon (14:00–17:00).  
351 Furthermore, the IR group seems to be more sensitive to the 0:00-5:00 am activity. This finding  
352 was not seen as an overall cohort (**Figure 5D**) but held, to a lesser extent, for other metabolic  
353 characteristics: lower CGM mean values from morning activity in the dysfunctional groups (i.e.,  
354 prediabetes, beta-cell dysfunction, incretin dysfunction), in contrast to benefits following  
355 afternoon activity in the normoglycemic groups (**Supplementary Figure 8**). Previous studies  
356 have shown mixed results when modifying timing of exercise on glycemic control. Consistent  
357 with our findings, one RCT study showed that morning moderate-intensity exercise improved  
358 metabolic benefits in individuals with diabetes<sup>27</sup>. However, other studies reported more  
359 efficacious glycemic control from afternoon or evening moderate-to-vigorous exercise or no  
360 differential effects between morning and afternoon exercises among people with or without type  
361 2 diabetes<sup>28-31</sup>. These inconsistencies across the studies may arise from variable intensity levels  
362 and modes of exercise used across the studies. Different exercise may trigger differential  
363 metabolic pathways of systemic glucose regulation, however, we could not determine the

364 intensity levels or specific types of activity of our participants solely based on their step count  
365 data. Nonetheless, our findings suggest that individuals with varying metabolic profiles (IS vs IR)  
366 may respond differently to the timing of increased activity, particularly those leading to higher  
367 step counts. Although the mechanism for this difference by activity timing is not clear, one  
368 possibility for the benefit of morning activity in the insulin-resistant group is through morning  
369 catecholamine peaks<sup>32</sup>. Perhaps morning exercise promotes skeletal muscle to uptake  
370 catecholamine-induced free fatty acids released from adipose tissues, and subsequently, an  
371 abnormality in lipid-induced insulin signaling could be ameliorated.

372 Not surprisingly, our data showed a significant association between sitting duration and  
373 less time in the night-time target glucose range, highlighting the importance of breaking up  
374 prolonged sitting as a first-line prevention/treatment regimen for glycemic regulation<sup>33</sup>. In  
375 support of this finding, we also observed CGM peaks within the range of HR/HRmax 0.32 to  
376 0.45, and the subsequent declines in CGM values when HR/HRmax surpassed 0.65 (**Figure**  
377 **5E**). This pattern highlights the importance of elevating HR/HRmax, which could be achieved by  
378 increasing activity such as aerobic training. Moreover, while a higher step density after eating  
379 the last food of the day (steps/hour) was associated with better night-time CGM outcomes, more  
380 steps close near bedtime (1-2 hours) associated with poor nighttime CGM outcomes. The data  
381 suggest that increased postprandial activity (after dinner) may be advantageous for glycemic  
382 control; however, increasing activity shortly before bedtime is unlikely to confer benefits. Future  
383 human studies with a rigorous design that considers exercise modes and granular time windows  
384 relative to meals are also warranted to accurately quantify the beneficial effects of exercise on  
385 glycemic end-points in people at risk for type 2 diabetes.

386 Finally, while the data above revealed individual associations between diet, sleep, and  
387 physical activity with glucose outcomes, we subsequently constructed comprehensive  
388 integrated prediction models. These models incorporated simultaneously all three lifestyle  
389 features along with demographic data (i.e., a total of 47 features) to predict various metabolic

390 characteristics. In our prediction models, dietary features, including nutrients, food groups, and  
391 eating timing, played a central role in distinguishing normal from dysfunctional groups as  
392 compared to other lifestyle features. This finding was further supported by our correlation  
393 network analysis, where we explored the simultaneous interrelationships among these three  
394 lifestyle behaviors. The data suggest that modifying dietary habits (i.e., both dietary composition  
395 and eating timing) may be the most powerful strategy to prevent and manage glucose  
396 dysregulation. Interestingly, a long-time gap between wake-up and first food time was a  
397 predictor for prediabetes or type 2 diabetes. Although the underlying mechanism is unclear, one  
398 possible explanation could be having first food relatively late after waking up in the morning  
399 could disrupt the circadian rhythm. Indeed, it was shown that important hormones and  
400 adipokines in glucose regulation peak during the first 5 hours after wake-up in animal studies<sup>34</sup>.

401 To our knowledge, this is the first study to explore how all three lifestyle factors are  
402 associated with metabolic phenotypes such as insulin resistance, beta-cell dysfunction, or  
403 incretin dysfunction, all of which could contribute to the development of type 2 diabetes. This  
404 investigation goes beyond standard clinical lab tests (e.g., HbA1c) and CGM data. We  
405 successfully built most final prediction models with excellent performance (**Supplementary**  
406 **Table 6**). Additionally, another strength of this study lies in examining the concurrent  
407 interrelationships among habitual lifestyle features captured in real-time by wearables and other  
408 digital health technologies.

409 This study revealed numerous novel associations between lifestyle patterns and glucose  
410 outcomes among participants at risk for type 2 diabetes residing in the SF Bay area. Thus, we  
411 acknowledge the possibility that the observed associations might not be generalizable to other  
412 populations. Additionally, as the data is observational rather than intervention-based, we cannot  
413 guarantee that the observed associations would hold true among individuals with prediabetes in  
414 an intervention setting. Future lifestyle intervention studies, especially those addressing timing  
415 considerations, are warranted.



416 We also acknowledge that lifestyle modifications might not be effective for everyone,  
417 particularly those with a genetic risk. Since our study did not genotype participants for common  
418 SNPs related to diabetes, we cannot exclude the possibility that the beneficial associations of  
419 lifestyle factors in our study may be specific to individuals with certain genetic variants  
420 predisposing them to diabetes. However, a recent large longitudinal cohort study<sup>35</sup>  
421 demonstrated that adopting a healthy lifestyle can mitigate the effects of genes associated with  
422 various diseases, including diabetes, by over 60%. Moreover, another recent intervention  
423 study<sup>36</sup> showed that lifestyle intervention was particularly effective in individuals at high genetic  
424 risk. Therefore, while we recognize that lifestyle modifications may not be universally effective,  
425 their value remains significant regardless of genetic or biological background. Future  
426 intervention studies are needed to explore the impact of lifestyle timing modifications on glucose  
427 regulation in individuals at risk due to genetic factors. Lastly, this human study had a relatively  
428 small sample size which might have limited the statistical power of the study findings. To  
429 address this limitation, we employed several methods, including permutation, cross-validation,  
430 and multiple testing correction to enhance validity and minimize bias in the data analysis. While  
431 the extensive and resource-intensive phenotyping resulted in a relatively modest sample size, it  
432 is the unique aspect of our study that enabled us to explore lifestyles and specific glucose  
433 metabolic traits.

434 This cohort is particularly important since there is a great benefit to delaying or  
435 preventing the onset of type 2 diabetes. Our study demonstrates that diet, sleep, and physical  
436 activity are strongly associated with divergent glucose outcomes measured objectively and  
437 concurrently by continuous glucose monitoring and extended standardized metabolic tests.  
438 Notably, the extensive associations reported here remain independent of BMI, ethnicity, age,  
439 and sex. Moreover, in our comprehensive prediction models, different metabolic characteristics  
440 are predicted by a different set of lifestyle features, implying the need for individual approaches

441 to improve lifestyle in this vulnerable population. Furthermore, the data suggest obvious diurnal  
442 patterns in lifestyle behaviors that influence glucose physiology and implicate the timing of food  
443 intake, sleep, and exercise could be a powerful behavioral regimen to ensure appropriate  
444 glycemic control. Overall, a future human intervention study coupled with multi-omics profiling is  
445 a logical next step to confirm the observed associations and address underlying molecular  
446 mechanisms.

447

## 448 **Methods**

### 449 **Study Design, Participants, and Sample Collection**

450 36 healthy adults (> 18 y of age; median 57.6y; 17 males and 19 females) were recruited  
451 from the San Francisco Bay Area, California. Inclusion criteria were general health, including no  
452 prior diabetes diagnosis and no diabetes medication. Participants underwent evaluations and  
453 screening tests at the Clinical and Translational Research Unit after overnight fasting (e.g.,  
454 HbA1c, fasting plasma glucose, insulin, lipid panel, and creatinine at baseline). The study  
455 protocol was reviewed and approved by the Institutional Review Board at Stanford University  
456 School of Medicine Human Research Protection Office (Institutional Review Board #43883). All  
457 participants provided written informed consent. This trial is registered on ClinicalTrials.Gov  
458 (NCT03919877; "*Precision Diets for Diabetes Prevention*"; 2019-04-18).

459

### 460 **Lifestyle Deep Profiling using Wearable Biosensors and Feature Extraction**

461 By leveraging the power of real-time digital health monitoring technologies, we  
462 monitored participants' dietary intake, sleep characteristics, physical activity, and glucose levels  
463 in real-time throughout the study period (at least 14 consecutive days). Participants were asked  
464 not to change their sleep and activity habits during the study. Moreover, participants were  
465 required to maintain their normal eating, sleep, and physical activity habits without change  
466 during the study.

467 For dietary data collection, participants were required to log all food and beverage items  
468 consumed in real-time on the Cronometer food tracking app (Cronometer Software, Inc.,  
469 Revelstoke, BC, Canada). A median of 20.5 days of food logs were collected from 36  
470 participants. Over 92% of participants provided more than 10 days of diet data during the study  
471 period. To enhance the accuracy of the diet data, days with a reported daily caloric intake of  
472 less than 500 kcal as well as those reporting an overnight fasting period exceeding 24 hours  
473 were excluded. Registered dietitians monitored participants' food log entries (food items,  
474 calories, and nutrient compositions) throughout the study. It was also ensured that all  
475 participants could record dietary intake data for at least two weekdays and one weekend day to  
476 capture a more accurate and representative understanding of their typical dietary habits. There  
477 was no missing dietary data for all 36 participants. A total of 74 diet features (51 energy-  
478 adjusted nutrient levels, 10 food groups, and 13 meal timings) were extracted (**Supplementary**  
479 **Table 1**).

480 For sleep and physical activity data collection, participants wore a Fitbit Ionic band (Fitbit,  
481 Inc., San Francisco, CA) for the study period. The Fitbit data was available for 24 out of 36  
482 participants due to a product recall of Fitbit Ionic for potential burn hazards during the study  
483 period. As such, a median of 47.5 nights of sleep data and 64 days of physical activity data  
484 were collected from 24 participants. To ensure data accuracy, only days with 4 to 12 hours of  
485 overnight sleep data were considered, and days with less than 500 steps were excluded. 14  
486 sleep features (1 quantity, 9 qualities, 4 timings) and 23 physical activity features (4 activity  
487 levels, 19 timings) were extracted (**Supplementary Table 1**). This study did not use the  
488 duration for each sleep stage because we did not have access to open-source Fitbit data to  
489 independently validate the algorithm predicting sleep structure in our population. Finally, heart  
490 rate (HR) data were also extracted.

491 For continuous glucose monitoring, participants wore a Dexcom G4 CGM device  
492 (Dexcom Inc., San Diego, CA) for the study period. Of note, readings from glucose monitoring

493 devices were not made available to the participants until the study-end, therefore, lifestyle habits  
494 were not affected by the recordings. CGM data were collected for a median of 36.5 days from all  
495 36 participants (14 to 69 days), with a median wear time of 23.5 hours per day.

496

#### 497 **Glucose Metabolic Physiological Tests**

498 Participants underwent glucose metabolic tests after 10-h overnight fasting to determine  
499 metabolic characteristics, such as insulin resistance, beta-cell dysfunction, and incretin  
500 dysfunction. The details of the physiologic tests will be published elsewhere and are  
501 summarized as follows.

502         Muscle insulin resistance was quantified through an insulin suppression test (IST). In a  
503 validated IST<sup>37,38</sup>, participants were infused with octreotide ( $0.27 \mu\text{g m}^{-2} \text{min}^{-1}$ ), insulin ( $32 \text{ mU m}^{-2}$   
504  $\text{min}^{-1}$ ), and glucose ( $267 \text{ mg m}^{-2} \text{min}^{-1}$ ) for 240 min. In this test, participants showed different  
505 levels of steady-state plasma glucose (SSPG), indicating the individual's ability of insulin-  
506 mediated glucose disposal<sup>12</sup>.

507         Beta cell function was assessed during an oral glucose tolerance test (OGTT).  
508 Specifically, plasma glucose levels were measured at 16 timepoints (-10, 0, 10, 15, 20, 30, 40,  
509 50, 60, 75, 90, 105, 120, 135, 150, and 180 min) following a 75g oral glucose load, while insulin  
510 and C-peptide were measured at 7 timepoints (0, 15, 30, 60, 90, 120, 180 min) using Millipore  
511 radioimmunoassay assay at the Core Lab for Clinical Studies, Washington University School of  
512 Medicine in St. Louis (WashU). The insulin secretion rate was calculated from C-peptide levels  
513 during the OGTT test using the Insulin SECreTion (ISEC) software. Then, a disposition index (DI;  
514  $(\text{pmol}\cdot\text{dL})/(\text{kg}\cdot\text{ml})$ )<sup>13</sup>, was calculated as the area under the insulin secretion rate, divided by the  
515 SSPG. Based on the DI, the beta cell function was determined.

516         Incretin function was quantified using an isoglycemic intravenous glucose infusion (IIGI)  
517 test. In an IIGI test, participants were infused with dextrose continuously via an intravenous

518 catheter. The incretin effect (IE%) can be quantified by comparing plasma glucose and C-  
519 peptide profiles responding to the dextrose load either orally (OGTT) or intravenously (IIGI).

520 The hepatic insulin resistance (HIR) index equation, using insulin, BMI, body fat%, and  
521 HDL cholesterol levels, was validated against endogenous glucose production measured during  
522 euglycemic–hyperinsulinemic clamp<sup>39</sup>. Adipose tissue insulin resistance was calculated based  
523 on the average plasma free fatty acid (FFA) measured at 90, 100, and 110 min during the  
524 modified IST.

525

## 526 **Statistical Analyses**

527 To test for differences in baseline demographics, labs, and metabolic test results  
528 between normoglycemia and prediabetes/type 2 diabetes groups, the Kruskal-Wallis test was  
529 used for non-normally distributed continuous variables, and the  $\chi^2$  test or Fisher's exact test  
530 was used for categorical variables.

531 To identify dietary patterns and their relationship to metabolic characteristics in the  
532 cohort, PCA was performed on meal timing features. They were classified/color-coded by  
533 HbA1c, insulin resistance SSPG, incretin effect, or beta-cell function DI. Then, we used  
534 covariate-adjusted multiple linear regression (MLR) models to examine differences in energy  
535 contribution of each meal timing between metabolic groups while adjusting for age, sex, BMI,  
536 and ethnicity. *P*-values were BH-adjusted for multiple testing.

537 To assess individual associations of diet, sleep, and activity features with glucose  
538 outcomes (CGM and metabolic test results), we used the least absolute shrinkage and selection  
539 operator (LASSO) combined with MLR. For each glucose outcome, we performed a grid search  
540 (values ranging from  $\lambda=10^{10}$  to  $\lambda=10^{-2}$ ) to optimize the hyperparameter and selected the model  
541 that minimizes test misclassification error (MSE). The LASSO models selected lifestyle features  
542 associated with glucose outcomes and provided an estimate of the predictive values of the  
543 feature individually (**Supplementary Tables 2,3,4**) Then, we used MLR to examine individual

544 associations of diet, sleep, and activity with glucose outcomes. *P*-values were BH-adjusted for  
545 multiple testing.

546 To examine the effects of the time series interaction between step counts and SSPG  
547 status on CGM mean values, linear models with permutation were fit at the 7-time windows of  
548 24 hours (05:00-8:00, 8:00-11:00, 11:00-14:00, 14:00-17:00, 17:00-21:00, 21:00-24:00, and  
549 24:00-the next day 05:00). Then, a shifted Pearson correlation analysis with permutation was  
550 performed between step counts and CGM mean values by SSPG status subgroups through the  
551 7-time windows. Moreover, to identify intercorrelations among the three lifestyles, we used  
552 Spearman correlation with permutation. All correlation and interaction analyses were adjusted  
553 for multiple testing.

554 Finally, we built integrated, comprehensive models based on all three lifestyle modalities  
555 and demographic information to predict metabolic characteristics. Since many features are  
556 highly dependent on each other, we removed obvious dependencies and kept a total of 47  
557 features to start with (e.g., baseline BMI was kept, and height and weight were removed).  
558 Features were then centered and scaled. Since we needed to include all three lifestyle factors  
559 simultaneously for building the prediction models, there were missing values for individuals  
560 without Fitbit data. We chose to use the cohort mean to replace these NA values, as MICE-  
561 imputed data failed to predict all metabolic classes. Next, the LASSO approach selected  
562 relevant features, and then models with no regularization were built<sup>39</sup>. The hyperparameter  
563 lambda was selected through leave-one-out. The model was selected based on the MSE. In all  
564 analyses, *P*-values were adjusted for multiple testing.

565

566 **Data Availability.** The datasets generated and/or analysed during the current study are  
567 available from the corresponding author on reasonable request. All nonPHI data will be shared  
568 indefinitely on a publicly available database at the time of publication. The data include CGM

569 (time-shifted), clinical information, and demographics. The study protocol is shared as a  
570 Supplementary Information.

571  
572 **Code Availability.** The underlying code for this study is available and can be accessed via this  
573 link ([https://github.com/mikeaalv/lifestyle\\_glucose\\_control](https://github.com/mikeaalv/lifestyle_glucose_control)).

574  
575 **Acknowledgments.** The authors thank the participants and investigators of the CGM 1.0 study.  
576 We thank Susan Kirkpatrick and Monika Avina for their efforts in conducting the research. We  
577 would like to thank artist Lettie McGuire for help in creating the graphical abstract for this  
578 manuscript. This study was funded by the National Institutes of Health (NIH)/NIDDK1R01  
579 DK110186-01 (M.P.S. and T.M.) and the Stanford PHIND award (M.P.S.). This study is part of  
580 the Precision Diets for Diabetes Prevention clinical trial (NCT03919877). H.P. was supported by  
581 the NIH institutional research training grant NIH 2T32HL09804911 and the Stanford Lifestyle  
582 Medicine grant. Y.W. was supported by the American Diabetes Association grant 11-23-PDF-76.  
583 We also acknowledge the support of the Stanford Diabetes Research Center (P30DK116074).

584  
585 **Author Contributions.** H.P., A.A.M., and M.P.S. conceptualized and designed the research;  
586 A.A.M., D.P., and A.C. conducted the research including sample collection; H.P., A.A.M., A.D.,  
587 Y.W., M.R., and C.M. analyzed and visualized the data; T.M., E.M., and M.S.P. advised  
588 interpretation of the data analysis and discussion; A.C. and D.P. administered research project  
589 administration; H.P. wrote the original draft of the manuscript; A.A.M., A.D., Y.W., C.M., D.P.,  
590 M.R., T.M., E.M., and M.P.S. reviewed and edited the manuscript. All authors approved the final  
591 version of the manuscript. M.P.S. is the guarantor of this work and, as such, had full access to  
592 all the data in the study and takes responsibility for the integrity of the data and the accuracy of  
593 the data analysis.

594

595 **Competing Interests.** A.A.M. is currently an employee of Google, and A.D. is an employee of  
596 Calico Life Sciences. D.P. and T.M. are members of the scientific advisory board of January AI.  
597 M.P.S. is a co-founder and a member of the scientific advisory board of Personalis, Qbio,  
598 January AI, SensOmics, Protos, Mirvie, RTHM and lollo. He is on the scientific advisory board  
599 of Danaher, Neuvivo and Jupiter. All other authors declare no financial or non-financial  
600 competing interests.

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620



621 **References**

- 622 1. International Diabetes Federation. IDF Diabetes Atlas 10th Edition. (2021).
- 623 2. Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J. & Kivimäki, M. Prediabetes: A  
624 high-risk state for diabetes development. *Lancet* **379**, 2279–2290 (2012).
- 625 3. Diabetes Prevention Program Research Group. Reduction of the incidence of type 2  
626 diabetes with lifestyle intervention or metformin. *N. Engl. J. Med.* **34**, 162–163 (2002).
- 627 4. Schüssler-Fiorenza Rose, S. M. *et al.* A longitudinal big data approach for precision  
628 health. *Nat. Med.* **25**, 792–804 (2019).
- 629 5. Li, X. *et al.* Digital Health: Tracking Physiomes and Activity Using Wearable Biosensors  
630 Reveals Useful Health-Related Information. *PLoS Biol.* **15**, e2001402 (2017).
- 631 6. Eckel-Mahan, K. & Sassone-Corsi, P. Metabolism and the circadian clock converge.  
632 *Physiol. Rev.* **93**, 107–135 (2013).
- 633 7. Gerhart-Hines, Z. & Lazar, M. A. Circadian metabolism in the light of evolution. *Endocr.*  
634 *Rev.* **36**, 289–304 (2015).
- 635 8. Dollet, L. & Zierath, J. R. Interplay between diet, exercise and the molecular circadian  
636 clock in orchestrating metabolic adaptations of adipose tissue. *J. Physiol.* **597**, 1439–  
637 1450 (2019).
- 638 9. Manoogian, E. N. C., Chow, L. S., Taub, P. R., Laferrère, B. & Panda, S. Time-restricted  
639 Eating for the Prevention and Management of Metabolic Diseases. *Endocr. Rev.* **43**,  
640 405–436 (2022).
- 641 10. Świątkiewicz, I., Woźniak, A. & Taub, P. R. Time-restricted eating and metabolic  
642 syndrome: Current status and future perspectives. *Nutrients* **13**, 1–24 (2021).
- 643 11. Sondrup, N. *et al.* Effects of sleep manipulation on markers of insulin sensitivity: A  
644 systematic review and meta-analysis of randomized controlled trials. *Sleep Med. Rev.* **62**,  
645 (2022).

- 646 12. Pei, D., Jones, C. N. O., Bhargava, R., Chen, Y. D. I. & Reaven, G. M. Evaluation of  
647 octreotide to assess insulin-mediated glucose disposal by the insulin suppression test.  
648 *Diabetologia* **37**, 843–845 (1994).
- 649 13. Hovorka, R., Soons, P. A. & Young, M. A. ISEC: A program to calculate insulin secretion.  
650 *Comput. Methods Programs Biomed.* **50**, 253–264 (1996).
- 651 14. Yeni-Komshian, H., Carantoni, M., Abbasi, F. & Reaven, G. M. Relationship between  
652 several surrogate estimates of insulin resistance and quantification of insulin-mediated  
653 glucose disposal in 490 healthy nondiabetic volunteers. *Diabetes Care* **23**, 171–175  
654 (2000).
- 655 15. Farshchi, H. R., Taylor, M. A. & Macdonald, I. A. Deleterious effects of omitting breakfast  
656 on insulin sensitivity and fasting lipid profiles in healthy lean women. *Am. J. Clin. Nutr.*  
657 **81**, 388–396 (2005).
- 658 16. Mekary, R. A. *et al.* Eating patterns and type 2 diabetes risk in older women: Breakfast  
659 consumption and eating frequency. *Am. J. Clin. Nutr.* **98**, 436–443 (2013).
- 660 17. Wu, T. *et al.* Differential Roles of Breakfast and Supper in Rats of a Daily Three-Meal  
661 Schedule Upon Circadian Regulation and Physiology. *Chronobiol. Int.* **28**, 890–903  
662 (2011).
- 663 18. Fuse, Y. *et al.* Differential roles of breakfast only (one meal per day) and a bigger  
664 breakfast with a small dinner (two meals per day) in mice fed a high-fat diet with regard  
665 to induced obesity and lipid metabolism. *J. Circadian Rhythms* **10**, 1 (2012).
- 666 19. Henry, C. J., Kaur, B. & Quek, R. Y. C. Chrononutrition in the management of diabetes.  
667 *Nutr. Diabetes* **10**, (2020).
- 668 20. Reutrakul, S., Punjabi, N. M. & Van Cauter, E. Impact of Sleep and Circadian  
669 Disturbances on Glucose Metabolism and Type 2 Diabetes. *Diabetes* 1–44 (2018).

- 670 21. Leproult, R., Holmbäck, U. & Van Cauter, E. Circadian misalignment augments markers  
671 of insulin resistance and inflammation, independently of sleep loss. *Diabetes* **63**, 1860–  
672 1869 (2014).
- 673 22. Reutrakul, S. & Van Cauter, E. Sleep influences on obesity, insulin resistance, and risk  
674 of type 2 diabetes. *Metabolism* **84**, 56–66 (2018).
- 675 23. Lee, S. W. H., Ng, K. Y. & Chin, W. K. The impact of sleep amount and sleep quality on  
676 glycemic control in type 2 diabetes: A systematic review and meta-analysis. *Sleep Med.*  
677 *Rev.* **31**, 91–101 (2017).
- 678 24. Huang, T., Wang, W., Zong, X. *et al.* Association Between Accelerometer-Measured  
679 Irregular Sleep Duration and Type 2 Diabetes Risk: A Prospective Cohort Study in the  
680 UK Biobank. *Diabetes Care* **46**, 1408–1416 (2023).
- 681 25. Poggiogalle, E., Jamshed, H. & Peterson, C. M. Circadian regulation of glucose, lipid,  
682 and energy metabolism in humans. *Metabolism* **84**, 11–27 (2018).
- 683 26. Gil-Lozano, M. *et al.* Short-term sleep deprivation with nocturnal light exposure alters  
684 time-dependent glucagon-like peptide-1 and insulin secretion in male volunteers. *Am. J.*  
685 *Physiol. Endocrinol. Metab.* **310**, E41–E50 (2015).
- 686 27. Gomez, A. M. *et al.* Effects of performing morning versus afternoon exercise on glycemic  
687 control and hypoglycemia frequency in type 1 diabetes patients on sensor-augmented  
688 insulin pump therapy. *J. Diabetes Sci. Technol.* **9**, 619–624 (2015).
- 689 28. Savikj, M. *et al.* Afternoon exercise is more efficacious than morning exercise at  
690 improving blood glucose levels in individuals with type 2 diabetes: a randomised  
691 crossover trial. *Diabetologia* **62**, 233–237 (2019).
- 692 29. Williams, R., Patel, S., Nguyen, T. *et al.* Impact of lifestyle moderate-to-vigorous physical  
693 activity timing on glycemic control in sedentary adults with overweight/obesity and  
694 metabolic impairments. *JAMA Intern. Med.* **180**, 789–797 (2021).

- 695 30. Smith, J., Doe, A., Brown, B. *et al.* Association of timing of moderate-to-vigorous  
696 physical activity with changes in glycemic control over 4 years in adults with type 2  
697 diabetes from the look AHEAD trial. *Diabetes Care* **45**, 123–130 (2023).
- 698 31. Teo, S. Y. M., Kanaley, J. A., Guelfi, K. J., Marston, K. J. & Fairchild, T. J. The Effect of  
699 Exercise Timing on Glycemic Control: A Randomized Clinical Trial. *Med. Sci. Sports*  
700 *Exerc.* **52**, 323–334 (2020).
- 701 32. Mancilla, R., Krook, A., Schrauwen, P. & Hesselink, M. K. C. Diurnal Regulation of  
702 Peripheral Glucose Metabolism: Potential Effects of Exercise Timing. *Obesity* **28**, S38–  
703 S45 (2020).
- 704 33. Remchak, M. M. E. *et al.* Considerations for maximizing the exercise “drug” to combat  
705 insulin resistance: role of nutrition, sleep, and alcohol. *Nutrients* **13**, 1–19 (2021).
- 706 34. Froy, O. & Garaulet, M. The circadian clock in white and brown adipose tissue:  
707 Mechanistic, endocrine, and clinical aspects. *Endocr. Rev.* **39**, 261–273 (2018).
- 708 35. Martinez, L., Wang, X., Chen, Y. *et al.* Genetic predisposition, modifiable lifestyles, and  
709 their joint effects on human lifespan: evidence from multiple cohort studies. *Nat.*  
710 *Commun.* **10**, 1234 (2020).
- 711 36. Johnson, M., Lee, C., Kim, D. *et al.* Effects of Genetic Risk on Incident Type 2 Diabetes  
712 and Glycemia: The T2D-GENE Lifestyle Intervention Trial. *Lancet Diabetes Endocrinol.*  
713 **11**, 456–465 (2022).
- 714 37. Greenfield, M. S., Doberne, L., Kraemer, F., Tobey, T. & Reaven, G. Assessment of  
715 insulin resistance with the insulin suppression test and the euglycemic clamp. *Diabetes*  
716 **30**, 387–392 (1981).
- 717 38. Shen, S. W., Reaven, G. M. & Farquhar, J. W. Comparison of impedance to insulin-  
718 mediated glucose uptake in normal subjects and in subjects with latent diabetes. *J. Clin.*  
719 *Invest.* **49**, 2151–2160 (1970).

720 39. Vangipurapu, J. *et al.* A novel surrogate index for hepatic insulin resistance. *Diabetologia*  
721 **54**, 540–543 (2011).

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746 **Figure Legends**

747 **Fig 1. Lifestyle Profiling and Glucose Metabolic Phenotyping.** We enrolled 36 participants  
748 mixed with normoglycemia, prediabetes, or type 2 diabetes. We collected 24 hours of real-time  
749 data on the lifestyle behaviors and glucose levels of the study participants for at least 14 days  
750 using wearable devices and smartphone applications. In addition, gold standard glucose  
751 metabolic tests were conducted (i.e., OGTT, IST, and IIGI tests) to determine participants'  
752 metabolic characteristics such as beta-cell dysfunction, incretin dysfunction, and insulin  
753 resistance.

754

755 **Figure 2 Meal timing patterns associated with distinct metabolic characteristics**

756 **a,** Heterogeneity in meal timing profiles between persons (n = 36). The food and beverage  
757 consumption (referred to as “meal”) periods were segmented into six windows. 1) 05:00 and  
758 08:00; 2) 08:00 and 11:00; 3) 11:00 and 14:00; 4) 14:00 and 17:00; 5) 17:00 and 21:00; and 6)  
759 21:00 and the next day 05:00. The energy intake contribution from each meal timing window  
760 relative to the total daily energy intake was determined. A bar indicates each participant.  
761 Different colors comprising the bar represent six meal timings. The length of the color  
762 corresponds to the contribution (%) of each meal to the total daily energy intake (100%).  
763 **b,** PCA plot showing the cohort separation by the six meal timing features. A circle-shaped point  
764 indicates each participant. The color gradation represents one’s HbA1c level ranging from low  
765 (yellow) to high (red).  
766 **c,** Box plots showing differences in energy contribution from six meal timings by glycemic status  
767 (normoglycemia when HbA1c<5.7% (HbA1c< 39 mmol/mol) and prediabetes when 5.7%  
768  $\leq$ HbA1c<6.5% (39 mmol/mol  $\leq$ HbA1c<48 mmol/mol)). Statistical significance was derived from  
769 the covariate-adjusted multiple linear regression models including HbA1c, age, sex, BMI, and  
770 ethnicity. The central line inside the box represents the median, and the error bars indicate 1.5  
771 times the IQR from the lower and upper quartiles. The symbols indicate a statistically significant

772 difference (BH-adjusted  $P$  value  $< 0.05$  for asterisk, and BH\_adjusted  $P$  value  $< 0.1$  for cross) in  
773 energy contribution from each meal timing between normoglycemia and prediabetes groups.  
774 PreDM, prediabetes.

775 **d**, PCA plot showing the cohort separation by the six meal timing features. A circle-shaped point  
776 indicates each participant. The color represents one's incretin effects ranging from low (yellow),  
777 intermediate (light green), to high (dark green).

778 **e**, Box plots showing differences in energy contribution from six meal timings by incretin effects.  
779 Statistical significance was derived from the covariate-adjusted multiple linear regression  
780 models including incretin effects %, age, sex, BMI, and ethnicity. The central line inside the box  
781 represents the median, and the error bars indicate 1.5 times the IQR from the lower and upper  
782 quartiles. The asterisk indicates a statistically significant difference in energy contribution from  
783 each meal timing among the incretin groups (BH-adjusted  $P$  value  $< 0.05$ ). IE, incretin effect.

784 **f**, PCA plot showing the cohort separation into two clusters by the six meal timing features. A  
785 point indicates each participant, and the different shapes and colors of the points represent  
786 muscle insulin sensitivity status (green circle for IS and orange triangle for IR).

787 **g**, Box plots showing differences in energy contribution from six meal timings by muscle insulin  
788 sensitivity. Statistical significance was derived from the covariate-adjusted multiple linear  
789 regression models including insulin sensitivity (SSPG), age, sex, BMI, and ethnicity. The central  
790 line inside the box represents the median, and the error bars indicate 1.5 times the IQR from the  
791 lower and upper quartiles. The asterisk indicates a statistically significant difference (BH-  
792 adjusted  $P$  value  $< 0.05$ ) in energy contribution from each meal timing between IS and IR  
793 groups. IS, insulin sensitive; IR, insulin resistant.

794

795 **Figure 3 Personal profiling of meal timing-related dietary habits and their associations**  
796 **with glucose metabolic outcomes.**

797 **a**, Violin plots showing timing-related diet features in the cohort. The violin plots illustrate kernel  
798 probability density of the data at different values and the horizontal bar depicts the median of  
799 the distribution. The error bars represent the data within 1.5 times the IQR from the lower and  
800 upper quartiles. First food time (am), time of eating the first food of the day; last food time (pm),  
801 time of eating the last food of the day; daily eating span (sec), eating time window between the  
802 first food and the last food; last food ~ bed time (sec), time spent from the last food till the bed  
803 time; wake-up time ~ first food (sec), time spent from wake-up in the morning till eating the first  
804 food. Sleep-related diet parameters were derived through time-matching.

805 **b**, Forest plot showing associations of diet parameters with glucose metabolic outcomes using  
806 LASSO feature selection combined with multiple linear regression. A horizontal panel in the plot  
807 represents each glucose outcome model (i.e., glucose metrics comprising metabolic tests and  
808 CGM). Associations that achieved statistical significance (BH-adjusted  $P < 0.1$ ) between diet  
809 parameters and glucose outcomes are listed in this figure. The coefficient of each diet feature (a  
810 point of estimate depicted as the central marker) was derived from the covariate-adjusted  
811 multiple linear regression models (all diet features, age, sex, BMI, and ethnicity). The error bars  
812 represent the 95% confidence interval for the point estimate. %E Meal, energy proportion (%) of  
813 the meal timing to the total daily energy intake; %Carb, carbohydrate proportion (%) of the food  
814 group out of the total daily carbohydrate intake from all food groups; FPG, fasting plasma  
815 glucose; IR, insulin resistant; SSPG, steady-state plasma glucose, representing muscle insulin  
816 resistance. Hyperglycemic range for 24h was defined as  $>140$  mg/dL, and for night time as  $>$   
817  $100$  mg/dL. Time in target range for 24h was defined as  $70$ - $140$  mg/dL and for night time as  $70$ -  
818  $100$  mg/dL.

819

820 **Figure 4 Personal profiling of sleep and physical activity habits and their associations**  
821 **with glucose metabolic outcomes.**



822 **a**, Violin plots showing sleep and physical activity habits and related timing features in the  
823 cohort. The violin plots illustrate kernel probability density of the data at different values and the  
824 horizontal bar depicts the median of the distribution. The error bars represent the data within 1.5  
825 times the IQR from the lower and upper quartiles. Total sleep duration is the actual time spent  
826 asleep, and latency duration is the time spent to accomplish the transition from full wakefulness  
827 to sleep onset. Sleep efficiency is determined by wake-up after sleep onset (WASO) divided by  
828 the total sleep duration. The midpoint of sleep is the clock time between sleep onset and wake  
829 up. Sedentary duration is the duration of "0" step count per day (minutes), and movement  
830 duration is the duration of non-zero step count per day (minutes). Active duration is the hours  
831 per day for which the step count > 250. Units for each panel are as follows: sec for total sleep  
832 duration, WASO, and latency; % for sleep efficiency; AM for the midpoint of sleep and wake-up  
833 time; PM (10, 11) and AM (0, 1, 2, 3) for bed time and sleep onset time. "Steps Last Food ~ Bed  
834 Time" and "Steps Wake-Up ~ First Food" features were derived by aligning the times of diet, sleep,  
835 and physical activity behaviors of each individual.

836 **b**, Forest plot showing associations of sleep parameters with glucose metabolic outcomes using  
837 LASSO feature selection combined with multiple linear regression. A horizontal panel in the plot  
838 represents each glucose outcome model (i.e., glucose metrics comprising metabolic tests and  
839 CGM). Associations that achieved statistical significance (BH-adjusted  $P < 0.1$ ) between sleep  
840 parameters and glucose outcomes are listed in this figure. The coefficient of each sleep feature  
841 (a point of estimate depicted as the central marker) was derived from the covariate-adjusted  
842 multiple linear regression models (all sleep features, age, sex, BMI, and ethnicity). The error  
843 bars represent the 95% confidence interval for the point estimate. Night-time was defined as the  
844 period during which participants took their night sleep, based on their Fitbit sleep data, and the  
845 hyperglycemic range for nighttime was defined as > 100 mg/dL. WASO, wake-up after sleep  
846 onset.

847 **c**, Forest plot showing associations of physical activity parameters with glucose metabolic  
848 outcomes using LASSO feature selection combined with multiple linear regression. A horizontal  
849 panel in the plot represents each glucose outcome model. Associations that achieved statistical  
850 significance (BH-adjusted  $P < 0.1$ ) between activity parameters and glucose outcomes are listed  
851 in this figure. The coefficient of each activity feature (a point of estimate depicted as the central  
852 marker) was derived from the covariate-adjusted multiple linear regression models (all activity  
853 features, age, sex, BMI, and ethnicity). The error bars represent the 95% confidence interval for  
854 the point estimate. Time in target range for night time was defined as 70-100 mg/dL.

855

856 **Figure 5 Time series associations between physical activity and sensor-glucose**  
857 **outcomes by insulin resistance status**

858 **a**, Interaction effects plot for step counts and SSPG status on CGM. Effects of step count and  
859 SSPG status on mean glucose values were assessed through linear models at each time  
860 window, permuted as in the Pearson correlation analysis. We split the time-series of step counts  
861 into 7-time windows of the day. The X-axis indicates the standardized step counts of a specific  
862 time window, and the Y-axis represents the corresponding glucose values up to the next 48  
863 hours. The orange line represents IR, and the green line IS, where interaction effects were  
864 considered significant (asterisk) if multiple testing-adjusted q-value  $< 0.01$ .

865 **b, c, d** Shifted correlation analysis plot between step count and CGM in different time windows  
866 of the day (b, Insulin-sensitive; c, Insulin-resistant; d, Overall cohort). We split the time-series of  
867 step counts into 7-time windows of the day, and correlations with CGM up to 48 hours were then  
868 calculated using permuted Pearson correlation and considered significant (asterisk) if multiple  
869 testing-adjusted q-value  $< 0.01$ . The color gradation represents correlation coefficients ranging  
870 from -0.5 (negative correlation) to 0.5 (positive correlation). CGM, continuous glucose  
871 monitoring.

872 **e**, 2D scatter plot that shows the distribution of CGM as a function of HR/HRmax for all  
873 participants over a shared period. Each point represents a data entry, color-coded by time of  
874 day (PST). The scatterplot shows a noticeable pattern between HR/HRmax and CGM values for  
875 all participants.

876

877 **Fig 6. Comprehensive lifestyle prediction of glucose metabolic characteristics and**  
878 **lifestyle modification suggestion.**

879 **a**, Diet, sleep and physical activity correlation network analysis. Concurrent correlations  
880 between lifestyle features were calculated using Spearman correlation with permutation and  
881 considered significant if multiple testing-adjusted q value < 0.2. The color gradation represents  
882 correlation coefficients ranging from -1.0 to 1.0. Different colors of points indicate different types  
883 of lifestyle features: light green (diet); purple (sleep); red (activity); dark green (combined  
884 features from diet and sleep); blue (combined features from diet, sleep, and activity).

885 **b**, Integrated lifestyle prediction model of metabolic characteristics. The LASSO classification  
886 model was built upon all lifestyle features, and model coefficients of selected features were  
887 visualized. The classifications are for Normoglycemia vs. PreDM/type 2 diabetes; Adipose IS vs  
888 IR; Incretin normal vs. intermediate vs. dysfunction; and Muscle IR vs. IS. Different colors  
889 indicate different types of lifestyle features. Sex (1 male, 0 female) and ethnicity (1 Caucasian, 0  
890 non-Caucasian) are two levels of numerical values. Latency is the time spent to accomplish the  
891 transition from full wakefulness to sleep onset. %E Meal, energy proportion (%) of the meal  
892 timing to the total daily energy intake; %Carb, carbohydrate proportion (%) of the food group out  
893 of the total daily carbohydrate intake from all food groups; Duration Wake-Up ~ First Food, the  
894 time gap between morning wake-up and the first food consumption; Movement/Sedentary  
895 Duration, the ratio of movement duration to sedentary duration; Education, the years of  
896 education; PreDM, prediabetes; IS, insulin sensitive; IR, insulin resistance. Nutrients (e.g., fat  
897 and sodium) are the daily dietary intakes of the corresponding nutrients.

898 **c**, Personalized lifestyle recommendation for glucose metabolic benefits. Pictorial summary of  
899 findings of this study (lifestyle recommendation for individuals with different insulin sensitivity).  
900 Boxes with different colors in both insulin-resistant and insulin-sensitive panels represent  
901 different types of lifestyle actions. Utensil icons in yellow and green boxes indicate % energy  
902 consumption during the corresponding time window. A running icon in a blue box indicates step  
903 counts during the corresponding time window. A horizontal bar in a pink box indicates consistent  
904 action (i.e., consistent bedtime). A bed icon in a gray box indicates sleep. An upward arrow in  
905 the boxes indicates increased action and a downward arrow indicates decreased action. For  
906 example, the upward arrow with the utensil icon in the yellow box indicates increased energy  
907 intake between 14:00-17:00 in IS or IR individuals. Boxes with different colors in the Glucose  
908 Control Benefit panel indicate the glucose control benefit effects by corresponding lifestyle  
909 intervention actions (matched colors). CGM, continuous glucose monitoring; FPG, fasting  
910 plasma glucose; HGR, hyperglycemic range (>100 mg/dL during the night); TIR, time in target  
911 range (70-100 mg/dL during the night).

912

913

914

915

916

917

918

919

920

921

922

923

924 **Table 1. Baseline demographics and clinical lab results of the study cohort**

	<b>Overall Cohort</b> (n = 36)	<b>Normal</b> (n=16)	<b>Prediabetes or T2D</b> (n=20)	<b>P-value</b>
<b>Demographics</b>				
Age, y	56.1 ± 11.4	53.5 ± 11.7	58.2 ± 10.9	0.324
Sex, n (M / F)	17 / 19	6 / 10	11 / 9	0.478
BMI, kg/m <sup>2</sup>	26.1 ± 3.39	25.4 ± 2.95	26.6 ± 3.72	0.427
Ethnicity, n (Caucasian / Asian)				
	26 / 9	14 / 2	12 / 7	0.135
Medication Statin Use, n (Yes / No)				
	2 / 34	1 / 15	1 / 19	1.000
Smoking, n (Yes / No)				
	2 / 25	1 / 10	1 / 13	1.000
Season at Study Entry, n (Spring / Summer / Fall / Winter)				
	4 / 13 / 9 / 9	3 / 3 / 4 / 6	1 / 10 / 5 / 3	0.128
Exercise, min	159 ± 114	204 ± 79.3	133 ± 126	0.0988
Systolic Blood Pressure, mmHg	116 ± 9.72	113 ± 8.97	119 ± 9.78	0.0946
Diastolic Blood Pressure, mmHg	72.5 ± 7.88	70.4 ± 7.27	74.1 ± 8.14	0.147
<b>Clinical Labs</b>				
HbA1c, %	5.64 ± 0.376	5.31 ± 0.224	5.90 ± 0.231	3.25e-07*

Fasting Plasma Glucose, mg/dL	97.9 ± 12.9	90.6 ± 10.6	104 ± 11.7	0.00161*
Triglyceride,mg/dL	93.2 ± 41.0	76.1 ± 33.4	107 ± 42.1	0.0142*
Total Cholesterol, mg/dL	188 ± 35.8	182 ± 27.1	193 ± 41.5	0.464
HDL, mg/dL	61.5 ± 19.5	62.8 ± 12.9	60.4 ± 23.8	0.171
LDL, mg/dL	108 ± 28.7	104 ± 27.1	111 ± 30.1	0.265
Non-HDL, mg/dL	126 ± 34.0	119 ± 31.5	132 ± 35.4	0.143
Fasting Insulin, mmol/L	9.54 ± 6.93	6.59 ± 3.57	12.0 ± 8.10	0.00930*
Creatinine, mg/dL	116 ± 70.6	121 ± 80.2	112 ± 63.3	0.921
hs-CRP, mg/L	1.19 ± 1.62	0.881 ± 0.854	1.44 ± 2.02	0.482
ALT/SGPT, U/L	27.3 ± 11.6	26.4 ± 9.95	28.1 ± 12.9	1.000


925 Continuous variables are reported as mean ± standard deviation, and categorical variables as count.

926 Asterisk in the P-value column indicates statistical significance ( $P < 0.05$ ) between normoglycemia

927 and prediabetes/T2D groups.

928

# Lifestyle Profiling



## Glucose Metabolic Phenotyping

### Metabolic Tests

- Oral glucose tolerance test (OGTT)
- Insulin suppression test (IST)
- Isoglycemic intravenous glucose infusion (IIGI)

### Clinical Lab


- HbA1c
- Fasting blood glucose
- Fasting insulin
- Lipid panel

### Continuous Glucose Monitoring


- Interstitial glucose measurement every 5 minutes




medRxiv preprint doi: <https://doi.org/10.1101/2024.09.10.24312545>; this version posted September 6, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




**b** PCA based on meal timing features colored by A1C




**d** PCA based on meal timing features colored by IE %




**f** PCA based on meal timing features colored by Muscle IR




**c**





**e**











**g**







**a****b**



**a****b****c****d****e**

**a****b****c**